ASBP
Price
$0.34
Change
-$0.05 (-12.82%)
Updated
Jun 5 closing price
Capitalization
N/A
ERAS
Price
$1.57
Change
+$0.04 (+2.61%)
Updated
Jun 5 closing price
Capitalization
444.76M
62 days until earnings call
Interact to see
Advertisement

ASBP vs ERAS

Header iconASBP vs ERAS Comparison
Open Charts ASBP vs ERASBanner chart's image
Aspire Biopharma Holdings
Price$0.34
Change-$0.05 (-12.82%)
Volume$1.7M
CapitalizationN/A
Erasca
Price$1.57
Change+$0.04 (+2.61%)
Volume$2.1M
Capitalization444.76M
ASBP vs ERAS Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASBP vs. ERAS commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASBP is a Hold and ERAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ASBP: $0.34 vs. ERAS: $1.57)
Brand notoriety: ASBP and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASBP: 43% vs. ERAS: 127%
Market capitalization -- ASBP: $0 vs. ERAS: $444.76M
ASBP [@Biotechnology] is valued at $0. ERAS’s [@Biotechnology] market capitalization is $444.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASBP’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ASBP’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both ASBP and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 7 TA indicator(s) are bullish.

  • ERAS’s TA Score: 7 bullish, 3 bearish.

Price Growth

ASBP (@Biotechnology) experienced а -43.56% price change this week, while ERAS (@Biotechnology) price change was +8.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.36%. For the same industry, the average monthly price growth was +17.10%, and the average quarterly price growth was +3.20%.

Reported Earning Dates

ASBP is expected to report earnings on May 14, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+11.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS YTD gains are higher at: -37.450 vs. ASBP (-97.043).
ASBPERASASBP / ERAS
CapitalizationN/A445M-
EBITDAN/A-151.33M-
Gain YTD-97.043-37.450259%
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A319M-
Total DebtN/A52.9M-
TECHNICAL ANALYSIS
Technical Analysis
ERAS
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY593.05-2.88
-0.48%
SPDR® S&P 500® ETF
AAPL200.63-2.19
-1.08%
Apple
GME29.45-0.50
-1.67%
GameStop Corp
BTC.X101575.950000-3156.031200
-3.01%
Bitcoin cryptocurrency
TSLA284.70-47.35
-14.26%
Tesla

ASBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASBP has been loosely correlated with SPRO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ASBP jumps, then SPRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASBP
1D Price
Change %
ASBP100%
-12.82%
SPRO - ASBP
58%
Loosely correlated
-3.57%
CLGN - ASBP
43%
Loosely correlated
-6.82%
ERAS - ASBP
29%
Poorly correlated
+2.61%
ALZN - ASBP
28%
Poorly correlated
-6.30%
ORIC - ASBP
28%
Poorly correlated
+0.88%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+2.61%
RVMD - ERAS
56%
Loosely correlated
-0.42%
LRMR - ERAS
56%
Loosely correlated
+0.41%
XNCR - ERAS
54%
Loosely correlated
+0.22%
ATXS - ERAS
53%
Loosely correlated
-1.14%
APGE - ERAS
53%
Loosely correlated
+3.10%
More